tsukiko.kurokawa@metagentx.com (Yamagata, Japan, April 15, 2024) Metagen Therapeutics, Inc. (Headquarters: Tsuruoka City, Yamagata Prefecture;President & CEO: Taku Nakahara), a company focusing on drug discovery and development of intestinal microbiome-based therapeutics for various diseases, will have its management team speaking at The 7th Annual Conference of Taiwan Microbiota Consortium & The 2nd Annual Conference of Asia Pacific Microbiota Consortium on April 27, 2024 in Taiwan.
Chief Medical Officer Dai Ishikawa (attending as Associate Professor of Juntendo University) and Chief Scientific Officer Jun Terauchi (attending as Steering Committee Chair of Japan Microbiome Consortium) will share their insights alongside internationally renowned scholars and experts from Taiwan, Japan, Australia, Korea, Singapore, Hong Kong and other countries.
The conference focuses on the latest development in the field of microbiome-related research. The theme of this year’s symposium will be “Challenges and Unmet Needs of Microbiome Research in the Era of Precision Health”.
■Schedule
11:30～11:55 Keynote Speech IV: Current Landscape and Future Perspective of Microbiome Based Drug Discovery and Development in the World
Jun Terauchi, Steering Committee Chair of Japan Microbiome Consortium
15:15～15:40 Parallel Session 5 : Fecal Microbiota Transplantation for Ulcerative Colitis in Japan : Super-Donor and Best Microbiota Matching
Dai Ishikawa, Assoc. Prof. of Juntendo University
For more information, please visit the following website: